PARP1 and cancer: The clinical development of Polθ inhibitors in Phase 1/2 trials for BRCA-deficient cancers, including ART6043, GSK4524101 and RP-3467, either alone or combined with PARP inhibitors, confirms the potential for Polθ for translation (81,82).